GNH USA

Europe — EMA

Myrelez (Lanreotide)

GNH USA supplies Myrelez (Lanreotide), a somatostatin analog for acromegaly and neuroendocrine tumor hormone control. Request a quote for global supply.

Lanreotide

Request sourcing

1
Pack/s

What is Lanreotide?

Lanreotide, the active ingredient in Myrelez, is a somatostatin analog presented as a sterile solution for subcutaneous injection. It is used to control excess hormone secretion in conditions such as acromegaly and certain neuroendocrine tumors, helping to normalize growth hormone and related peptide levels in affected patients.

GNH USA supplies Myrelez as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

What is Lanreotide used for?

Myrelez (lanreotide) is employed in endocrine‑related disorders where somatostatin pathways are overactive.

Acromegaly: reduces excess growth hormone secretion and helps normalize insulin‑like growth factor‑1 levels. Neuroendocrine tumors (GEP‑NET): controls hormone‑related symptoms and may slow tumor progression. Carcinoid syndrome: alleviates flushing, diarrhea and other secretory symptoms associated with serotonin‑producing tumors.

What are the side effects of Lanreotide?

Lanreotide may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain or erythema - Nausea - Diarrhea - Headache - Hyperglycemia - Abdominal discomfort

Serious or Rare Side Effects: - Gallbladder disease or biliary sludge - Acute pancreatitis - Severe hyperglycemia requiring medical intervention - Anaphylactic reactions - Cardiac arrhythmias (rare)

What precautions apply to Lanreotide?

Before initiating Myrelez, clinicians should consider several safety measures.

Glucose monitoring: patients with diabetes should have blood glucose checked regularly. Gallbladder assessment: evaluate for gallstones before initiating therapy. Hypersensitivity: discontinue if signs of allergic reaction appear. Renal function: adjust use in severe renal impairment. Concomitant hormone therapy: monitor for additive effects. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

What does Lanreotide interact with?

Lanreotide can interact with other medicines, requiring attention to avoid or monitor effects.

Major Interactions (Avoid): - Cyclosporine: may increase lanreotide plasma concentrations. - Octreotide or other somatostatin analogs: additive hormonal suppression. - Concomitant use with other long‑acting injectable peptides: risk of overlapping adverse effects.

Moderate Interactions (Monitor Closely): - Insulin or oral hypoglycemic agents: lanreotide can alter glucose control, requiring dose adjustments. - Antidiabetic medications: monitor blood sugar closely.

Frequently asked questions

What is Myrelez used for?+
Myrelez contains lanreotide, a somatostatin analog indicated for the treatment of acromegaly and for control of hormone‑related symptoms in gastroenteropancreatic neuroendocrine tumors and carcinoid syndrome. It helps reduce excess growth hormone and other peptide hormones in these conditions.
How does lanreotide work?+
Lanreotide mimics natural somatostatin and binds to somatostatin receptors (mainly subtypes 2 and 5) on endocrine cells. This binding inhibits adenylate cyclase, lowers cyclic AMP, and suppresses the release of growth hormone, insulin, glucagon, gastrin and other peptides, thereby controlling hormone‑driven disease processes.
What is the usual dose of Myrelez?+
The specific dose and dosing interval of Myrelez are determined by the prescribing clinician based on the patient’s condition, disease severity and response to therapy. Healthcare providers select the appropriate strength and administration schedule in accordance with approved labeling and clinical guidelines.
Is Myrelez safe during pregnancy or breastfeeding?+
Safety of lanreotide in pregnancy and lactation has not been fully established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.
How do I order Myrelez from GNH USA?+
To request Myrelez, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.
How does Myrelez compare with other somatostatin analogs?+
Myrelez (lanreotide) and other agents such as octreotide share the same mechanism of receptor activation but differ in formulation and dosing frequency. Lanreotide is available as a long‑acting injectable that can be administered every 4–8 weeks, whereas octreotide often requires more frequent dosing, which may influence convenience and adherence.
How should Myrelez be stored and handled?+
Myrelez should be stored at 2–8 °C in a refrigerator, protected from light and moisture. Do not freeze the product or shake the vial vigorously. If temporary storage at controlled room temperature is unavoidable, use it within the time frame specified in the product labeling.
How is Myrelez administered?+
Myrelez is given by subcutaneous injection, typically using a prefilled syringe or autoinjector. The injection site is rotated among the abdomen, thigh or upper arm to reduce local irritation. Administration is performed by a qualified healthcare professional or trained patient following aseptic technique.
What are the most serious risks associated with Myrelez?+
Serious adverse events reported with lanreotide include gallbladder disease (such as biliary sludge or cholelithiasis), acute pancreatitis, severe hyperglycemia that may require medical intervention, and rare anaphylactic reactions. Patients should be monitored for symptoms of these conditions and seek immediate medical attention if they occur.
Who should not use Myrelez?+
Myrelez is contraindicated in individuals with known hypersensitivity to lanreotide or any of the excipients in the formulation. Caution is also advised for patients with severe renal impairment, uncontrolled diabetes, or existing gallbladder disease, and it should be avoided in these situations unless the prescribing physician determines that benefits outweigh risks.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Lanreotide
Route
Subcutaneous Use
Manufacturer
Amdipharm Limited
Origin
EU

Related products

Ipstyl

Ipstyl

Lanreotide

Ipsen S.P.A.
EU
Ipstyl Autogel

Ipstyl Autogel

Lanreotide

Institut Produits Synthèse (Ipsen) Ab
EU
Ipstyl Autogel

Ipstyl Autogel

Lanreotide

Institut Produits Synthèse (Ipsen) Ab
EU
Lanrenet

Lanrenet

Lanreotide

Mylan S.P.A.
EU